Theranexus is a pioneer in the design and development of treatments acting on the interaction between neurons and glial cells in response to the needs of patients with nervous system diseases.

Theranexus’ IPO in 2017.

heads

Franck MOUTHON

Mathieu CHARVERIAT

Julien VEYS

Werner REIN

Investor

Isabelle BOU ANTOUN